Is New ZW191 and Pan-RAS ADC Data Acceptance Shifting The Investment Case For Zymeworks (ZYME)?

Simply Wall St.03-30

In March 2026, Zymeworks Inc. reported that an oral presentation of new Phase 1 clinical data for its folate receptor alpha-targeting antibody-drug conjugate ZW191, along with six additional abstracts...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623350686?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-30 03:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623350686","market":"sg","top_or_hot":-1,"title":"Is New ZW191 and Pan-RAS ADC Data Acceptance Shifting The Investment Case For Zymeworks (ZYME)?","media":"Simply Wall St.","content":"<div>\n<p>In March 2026, Zymeworks Inc. reported that an oral presentation of new Phase 1 clinical data for its folate receptor alpha-targeting antibody-drug conjugate ZW191, along with six additional abstracts...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zyme/zymeworks/news/is-new-zw191-and-pan-ras-adc-data-acceptance-shifting-the-in\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is New ZW191 and Pan-RAS ADC Data Acceptance Shifting The Investment Case For Zymeworks (ZYME)?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs New ZW191 and Pan-RAS ADC Data Acceptance Shifting The Investment Case For Zymeworks (ZYME)?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-30 03:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zyme/zymeworks/news/is-new-zw191-and-pan-ras-adc-data-acceptance-shifting-the-in><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In March 2026, Zymeworks Inc. reported that an oral presentation of new Phase 1 clinical data for its folate receptor alpha-targeting antibody-drug conjugate ZW191, along with six additional abstracts...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zyme/zymeworks/news/is-new-zw191-and-pan-ras-adc-data-acceptance-shifting-the-in\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4231","symbol_name":"零售房地产信托","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zyme/zymeworks/news/is-new-zw191-and-pan-ras-adc-data-acceptance-shifting-the-in","article_id":"2623350686","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zyme/zymeworks/news/is-new-zw191-and-pan-ras-adc-data-acceptance-shifting-the-in","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2623350686","pubTimestamp":1774811312,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In March 2026, Zymeworks Inc. reported that an oral presentation of new Phase 1 clinical data for its folate receptor alpha-targeting antibody-drug conjugate ZW191, along with six additional abstracts from its wholly owned oncology R&D portfolio, had been accepted for the American Association for Cancer Research Annual Meeting in San Diego.\nThe breadth of clinical and preclinical data, spanning ZW191 and multiple pan-RAS inhibitor antibody-drug conjugate candidates across RAS-mutated and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4231":"零售房地产信托","BK4080":"零售业房地产投资信托","ZYME":"ZYMEWORKS INC (US)","BK4139":"生物科技","ADC":"艾格里房产"},"translate_title":"新的ZW191和泛RAS ADC数据的接受是否会改变Zymeworks(ZYME)的投资案例？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZYME":1.5,"ADC":1.5},"content_text":"In March 2026, Zymeworks Inc. reported that an oral presentation of new Phase 1 clinical data for its folate receptor alpha-targeting antibody-drug conjugate ZW191, along with six additional abstracts from its wholly owned oncology R&D portfolio, had been accepted for the American Association for Cancer Research Annual Meeting in San Diego. The breadth of clinical and preclinical data, spanning ZW191 and multiple pan-RAS inhibitor antibody-drug conjugate candidates across RAS-mutated and folate receptor alpha-positive cancers, underscores Zymeworks’ attempt to build a differentiated oncology platform targeting areas of high unmet medical need. We’ll now examine how the encouraging early ZW191 data and broader pan-RAS ADC platform may influence Zymeworks’ existing investment narrative. We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.AdvertisementZymeworks Investment Narrative RecapTo own Zymeworks, you need to believe its mix of partnered revenues and a high-risk, early-stage oncology pipeline can eventually support a sustainable, less lumpy business. The AACR data for ZW191 and the broader pan RAS ADC platform reinforce that pipeline story, but they do not change the near term reality that the key catalyst and risk still center on milestone timing and royalties from partners like Jazz and BeOne versus ongoing cash burn. Among recent updates, the US$299.4 million cash balance and expectation of funding into the second half of 2027 stand out against this AACR news. Strong early ZW191 and pan RAS data may strengthen Zymeworks’ scientific case, but unless and until they translate into later stage trials or new collaborations, the most tangible near term support for the thesis remains the existing cash runway and anticipated regulatory milestones. Yet against the excitement around AACR, investors should be aware that prolonged net losses and reliance on episodic milestones could still... Read the full narrative on Zymeworks (it's free!)Zymeworks' narrative projects $150.9 million revenue and $24.2 million earnings by 2028. This requires 7.1% yearly revenue growth and a $97.9 million earnings increase from $-73.7 million today.Uncover how Zymeworks' forecasts yield a $36.46 fair value, a 51% upside to its current price.Exploring Other PerspectivesZYME 1-Year Stock Price Chart Some of the lowest estimate analysts were assuming revenue could shrink about 3.7 percent a year and still only reach around US$120.2 million by 2029, which is far more cautious than the baseline view and keeps earnings expectations muted compared with the potential they see in ZW191 and the pan RAS platform.Explore 2 other fair value estimates on Zymeworks - why the stock might be worth as much as 89% more than the current price!Decide For YourselfDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Zymeworks research is our analysis highlighting 3 key rewards that could impact your investment decision.Our free Zymeworks research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zymeworks' overall financial health at a glance.Interested In Other Possibilities?Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.Find 62 companies with promising cash flow potential yet trading below their fair value.This technology could replace computers: discover 22 stocks that are working to make quantum computing a reality.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Zymeworks might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623350686","isCrawlerRequest":true}